Payment overview · 2025
General Payments
$1,679.81
81 reported records · 24 companies
Healthcare provider profile · identity verified
Julian Ambrus, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Allergy & Immunology · WILLIAMSVILLE, NY · NPI 1811919988
Verified facts
What the public records show
CMS Open Payments records show Julian Ambrus, MD received $1,679.81 in general payments during 2025 across 81 reported records.
ABBVIE INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Hizentra by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Privigen as an associated drug or biological on 464 records involving 289 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Privigen by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 98 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $321.57 | 19.1% | 15 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $226.21 | 13.5% | 12 | 2025 |
| BioCryst US Sales Co., LLC | Unresolved — no canonical attribution shown | $184.56 | 11.0% | 10 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $144.40 | 8.6% | 6 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $101.82 | 6.1% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $80.63 | 4.8% | 3 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $71.28 | 4.2% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.84 | 3.7% | 3 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $54.80 | 3.3% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $53.41 | 3.2% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.51 | 2.8% | 2 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $43.25 | 2.6% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.78 | 2.3% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $34.26 | 2.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.85 | 1.7% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.24 | 1.7% | 1 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $27.38 | 1.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.75 | 1.5% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $21.45 | 1.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $21.23 | 1.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.06 | 1.1% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $17.40 | 1.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.58 | 0.8% | 1 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $13.55 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,679.81 | 81 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $219.66 | 10 | 2025 |
Source payment records
|
|||||
| ORLADEYO Normalized: orladeyo |
Drug | BioCryst US Sales Co., LLC | $184.56 | 10 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $144.40 | 6 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $135.02 | 7 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $105.87 | 5 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $101.91 | 5 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $80.63 | 3 | 2025 |
Source payment records
|
|||||
| CUVITRU Normalized: cuvitru |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $55.26 | 2 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $53.41 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $47.11 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $47.11 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $43.88 | 2 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $43.25 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $38.78 | 2 | 2025 |
Source payment records
|
|||||
| Kineret Normalized: kineret |
Drug | SOBI, INC | $34.26 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $30.02 | 1 | 2025 |
Source payment records
|
|||||
| DAWNZERA Normalized: dawnzera |
Drug | Ionis Pharmaceuticals, Inc. | $28.24 | 1 | 2025 |
Source payment records
|
|||||
| Xembify Normalized: xembify |
Biological | Grifols USA, LLC | $27.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $24.08 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| AYVAKIT Normalized: ayvakit |
Biological | GENZYME CORPORATION | $21.60 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $21.45 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $21.23 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.06 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $17.49 | 1 | 2025 |
Source payment records
|
|||||
| Sajazir Normalized: sajazir |
Drug | Cycle Pharmaceuticals Inc | $17.40 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $16.02 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $13.58 | 1 | 2025 |
Source payment records
|
|||||
| Andembry Normalized: andembry |
Biological | CSL Behring | $13.55 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Privigen open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 289 recipient NPIs · example record 1232339064 |
Privigen · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
98 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levocarnitine | Levocarnitine | 657 | 169 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 285 | 58 |
| Azelastine Hcl | Azelastine Hcl | 202 | 84 |
| Cevimeline Hcl | Cevimeline Hcl | 177 | 41 |
| Folic Acid | Folic Acid | 171 | 39 |
| Verapamil Hcl | Verapamil Hcl | 163 | 54 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 148 | 30 |
| Nimodipine | Nimodipine | 135 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 129 | 38 |
| Meloxicam | Meloxicam | 121 | 32 |
| Cilostazol | Cilostazol | 109 | 31 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 98 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 84 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 77 | 20 |
| Pilocarpine Hcl | Pilocarpine Hcl | 72 | 25 |
| Budesonide Dr | Budesonide | 70 | 21 |
| Mesalamine | Mesalamine | 63 | 12 |
| Privigen | Immun Glob G(Igg)/Pro/Iga 0-50 | 63 | suppressed |
| Verapamil Sr | Verapamil Hcl | 63 | 26 |
| Methotrexate | Methotrexate Sodium | 58 | 11 |
| Baclofen | Baclofen | 55 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 53 | suppressed |
| Gabapentin | Gabapentin | 51 | 12 |
| Omeprazole | Omeprazole | 51 | 16 |
| Potassium Chloride | Potassium Chloride | 51 | 14 |
| Verapamil Er | Verapamil Hcl | 50 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 11 |
| Azithromycin | Azithromycin | 48 | 34 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 48 | suppressed |
| Pentoxifylline | Pentoxifylline | 47 | 13 |
| Montelukast Sodium | Montelukast Sodium | 42 | 11 |
| Prednisone | Prednisone | 40 | suppressed |
| Dextrose In Water | Dextrose 70 % In Water | 39 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | suppressed |
| Budesonide Ec | Budesonide | 38 | 15 |
| Sulfasalazine | Sulfasalazine | 38 | suppressed |
| Nicardipine Hcl | Nicardipine Hcl | 34 | 11 |
| Albuterol Sulfate | Albuterol Sulfate | 33 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 33 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 32 | 18 |
| Diazepam | Diazepam | 31 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 31 | suppressed |
| Erythromycin | Erythromycin Base | 29 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 26 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Colchicine | Colchicine | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 11 |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Budesonide Er | Budesonide | 20 | suppressed |
| Eliquis | Apixaban | 20 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 18 | 13 |
| Leflunomide | Leflunomide | 18 | suppressed |
| Levocarnitine | Levocarnitine (With Sugar) | 18 | suppressed |
| Alprazolam | Alprazolam | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 16 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 16 | suppressed |
| Furosemide | Furosemide | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Azathioprine | Azathioprine | 13 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Fragmin | Dalteparin Sodium,porcine | 13 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | 11 |
| Humira(Cf) Pen | Adalimumab | 12 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Magnesium Sulfate | Magnesium Sulfate | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Scopolamine | Scopolamine | 12 | suppressed |
| Solu-Cortef | Hydrocortisone Sodium Succ/Pf | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Valganciclovir Hcl | Valganciclovir Hcl | 12 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,679.81 · 81 records | ABBVIE INC. | ACTHAR, AYVAKIT, Andembry, BENLYSTA, Bimzelx, CUVITRU, Cologuard Collection Kit, DAWNZERA, DUPIXENT, EVENITY, JARDIANCE, Kineret, LAGEVRIO, NURTEC ODT, ORLADEYO, OTEZLA, Ozempic, PAXLOVID, PROLIA, PYRUKYND, RINVOQ, Rybelsus, SAPHNELO, SKYRIZI, Sajazir, TAVNEOS, TRELEGY ELLIPTA, TREMFYA, TRINTELLIX, The Cologuard Plus Collection Kit, UPLIZNA, VERQUVO, XIFAXAN, Xembify | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with CSL Behring?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error